HDAC1 inhibitors have demonstrated efficacy in the treatment of several cancers, including gastric, breast, colorectal, prostate, colon, lung, ovarian, and pancreatic cancers, as well as in managing inflammation, with minimal associated toxic effects [21–24]. The gene discussed is HDAC1; the disease is familial pancreatic carcinoma.